晚期非小细胞肺癌患者D-二聚体水平的临床价值  

Clinical value of D-dimer level in patients with advanced non-small cell lung cancer

作　　者：李敬国 段爱雄[1] 江启安[1] 汪志求[1] 韩光锋[1] LI Jingguo;DUAN Aixiong;JIANG Qi′an;WANG Zhiqiu;HAN Guangfeng(Department of Oncology,Anqing Municipal Hospital,Anqing 246003,China)

机构地区：[1]安徽医科大学附属安庆医院肿瘤内科,安徽安庆246003

出　　处：《皖南医学院学报》2018年第2期137-139,共3页Journal of Wannan Medical College

摘　　要：目的:研究晚期非小细胞肺癌(NSCLC)患者D-二聚体水平的临床价值。方法:对2014年1月~2016年3月我科收治的晚期非小细胞肺癌患者D-二聚体水平进行跟踪监测,直至患者死亡或者随访结束,分析患者D-二聚体水平与临床病理特征、疗效以及预后的关系。结果:多部位转移较单部位转移的患者D-二聚体水平高(P<0.05),而D-二聚体水平与年龄、性别、病理类型无明显相关性;基线D-二聚体水平正常(≤0.5 mg/L)和升高(>0.5 mg/L)的中位总生存时间分别是24.1和16.0个月(P<0.01);两程化疗后疗效评价为缓解(PR):患者D-二聚体水平下降(P<0.01),进展(PD):患者D-二聚体水平升高(P<0.01);死亡患者中死亡前12个月开始D-二聚体水平逐渐升高(P<0.01)。结论:D-二聚体水平变化基本能反映患者的治疗效果,D-二聚体水平对患者生存时间的预测有意义。Objective:To evaluate the clinical value of D-dimer level in patients with advanced non-small cell lung cancer(NSCLC).Methods:D-dimer level was measured in patients with advanced NSCLC,treated in our department from January 2014 to March 2016,till the death or completion of follow-up.The relationship was analyzed between D-dimer level and clinicopathological properties,therapeutic effect and prognosis.Results:Patients with multiple metastasis had higher D-dimer level than those with single metastasis(P<0.05),however,D-dimer level not associated with the age,gender and pathological type The median overall survival was 24.1 months and 16.0 months for patients with baseline level of D-dimer at normal(>0.5 mg/L)and increased by(≤0.5 mg/L),respectively,(P<0.01).The D-dimer level was significantly decreased in patients following two courses of chemotherapy(partial remission by evaluation),yet increased in those with progressive disease(P<0.01).D-dimer level tended to increase in patients 12 months before death(P<0.01).Conclusion:D-dimer level change can reflect the curative effect in patient with NSCLC,and be used as indicators to predict the survival of the patients.

关 键 词：非小细胞肺癌 D-二聚体 化疗 预后 死亡 

分 类 号：R734.2[医药卫生—肿瘤] R446.11[医药卫生—临床医学]